InterCure Ltd
TASE:INCR
Intrinsic Value
InterCure Ltd. engages in the business of medical cannabis and biomedicine. [ Read More ]
The intrinsic value of one INCR stock under the Base Case scenario is 1 358.42 ILS. Compared to the current market price of 1 228 ILS, InterCure Ltd is Undervalued by 10%.
Valuation Backtest
InterCure Ltd
Run backtest to discover the historical profit from buying and selling INCR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
InterCure Ltd
Current Assets | 394.5m |
Cash & Short-Term Investments | 102.8m |
Receivables | 134.4m |
Other Current Assets | 157.3m |
Non-Current Assets | 447.3m |
Long-Term Investments | 42.6m |
PP&E | 97m |
Intangibles | 284.2m |
Other Non-Current Assets | 23.6m |
Current Liabilities | 207.8m |
Accounts Payable | 144.1m |
Short-Term Debt | 957k |
Other Current Liabilities | 62.7m |
Non-Current Liabilities | 125.3m |
Long-Term Debt | 105.4m |
Other Non-Current Liabilities | 20m |
Earnings Waterfall
InterCure Ltd
Revenue
|
414.8m
ILS
|
Cost of Revenue
|
-265.3m
ILS
|
Gross Profit
|
149.5m
ILS
|
Operating Expenses
|
-109.5m
ILS
|
Operating Income
|
40m
ILS
|
Other Expenses
|
-19.1m
ILS
|
Net Income
|
20.9m
ILS
|
Free Cash Flow Analysis
InterCure Ltd
INCR Profitability Score
Profitability Due Diligence
InterCure Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
Score
InterCure Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.
INCR Solvency Score
Solvency Due Diligence
InterCure Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
InterCure Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INCR Price Targets Summary
InterCure Ltd
Shareholder Return
INCR Price
InterCure Ltd
Average Annual Return | -20.38% |
Standard Deviation of Annual Returns | 36.53% |
Max Drawdown | -91% |
Market Capitalization | 590.5m ILS |
Shares Outstanding | 480 884 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
InterCure Ltd. engages in the business of medical cannabis and biomedicine. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
Contact
IPO
Employees
Officers
The intrinsic value of one INCR stock under the Base Case scenario is 1 358.42 ILS.
Compared to the current market price of 1 228 ILS, InterCure Ltd is Undervalued by 10%.